Welcome to our dedicated page for PROVECTUS BIOPHARMACEUTICALS SEC filings (Ticker: PVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PROVECTUS BIOPHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PROVECTUS BIOPHARMACEUTICALS's regulatory disclosures and financial reporting.
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals (PVCT), converted an 8% unsecured convertible promissory note issued under the company's 2024 financing into preferred and common shares. The $175,000 2024 Note converted on 09/30/2025 into 66,052 shares of Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share. Each Series D-1 share is convertible into 10 shares of common stock, producing 660,520 common shares underlying the preferred shares. The filing shows 2,484,499 shares of common stock beneficially owned following the reported transactions. The Series D-1 automatically converts into common stock on 06/20/2026 unless earlier converted under its terms.
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted a 2024 unsecured convertible promissory note into equity on September 19, 2025. The $100,000 8% note, originally issued under the companys 2024 financing and convertible at $2.862 per share into Series D-1 Preferred Stock, converted into 37,760 shares of Series D-1 Preferred Stock on that date. Each Series D-1 share is convertible into ten shares of common stock, so the conversion corresponds to 377,600 shares of common stock. Following the transaction, Mr. Pershing beneficially owned 2,418,447 shares of common stock. The Series D-1 will automatically convert to common on June 20, 2026 unless earlier converted under its terms.
Insider transaction summary: The company's CEO and a director, Edward Pershing, acquired an 8% unsecured convertible promissory note with a principal amount of $35,000 issued under the issuer's 2025 financing, which is convertible at $2.862 per share into Series D-1 Convertible Preferred Stock. The note may be voluntarily converted at any time while outstanding and will automatically convert into Series D-1 Preferred Stock one year after issuance. Each Series D-1 Preferred share converts into 10 shares of common stock, and the reported Series D-1 Preferred position equals 12,230 shares (effectively 122,300 common shares if converted). The Series D-1 Preferred will automatically convert into common on the specified conversion date absent earlier conversion.
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals (PVCT), reported a transaction dated 09/11/2025. He acquired an 8% unsecured convertible promissory note with a principal amount of $35,000 that is convertible into Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share. Following the reported transaction he beneficially owns 12,230 shares of Series D-1 Preferred Stock. Each Series D-1 Preferred share is convertible into 10 shares of common stock, and the Series D-1 Preferred will automatically convert into common stock on June 26, 2026 unless converted earlier. The Note will automatically convert into Series D-1 Preferred twelve months after issuance if not voluntarily converted earlier.